Most Cited Articles | Alzheimer’s Disease Classification Based on Multi-feature Fusion

Journal Name: Current Medical Imaging
Formerly: Current Medical Imaging Reviews

 

Author(s): Nuwan Madusanka, Heung-Kook Choi*, Jae-Hong So, Boo-Kyeong Choi.

Graphical Abstract:

Abstract:

Background: In this study, we investigated the fusion of texture and morphometric features as a possible diagnostic biomarker for Alzheimer’s Disease (AD).

Methods: In particular, we classified subjects with Alzheimer’s disease, Mild Cognitive Impairment (MCI) and Normal Control (NC) based on texture and morphometric features. Currently, neuropsychiatric categorization provides the ground truth for AD and MCI diagnosis. This can then be supported by biological data such as the results of imaging studies. Cerebral atrophy has been shown to correlate strongly with cognitive symptoms. Hence, Magnetic Resonance (MR) images of the brain are important resources for AD diagnosis. In the proposed method, we used three different types of features identified from structural MR images: Gabor, hippocampus morphometric, and Two Dimensional (2D) and Three Dimensional (3D) Gray Level Co-occurrence Matrix (GLCM). The experimental results, obtained using a 5-fold cross-validated Support Vector Machine (SVM) with 2DGLCM and 3DGLCM multi-feature fusion approaches, indicate that we achieved 81.05% ±1.34, 86.61% ±1.25 correct classification rate with 95% Confidence Interval (CI) falls between (80.75-81.35) and (86.33-86.89) respectively, 83.33%±2.15, 84.21%±1.42 sensitivity and 80.95%±1.52, 85.00%±1.24 specificity in our classification of AD against NC subjects, thus outperforming recent works found in the literature. For the classification of MCI against AD, the SVM achieved a 76.31% ± 2.18, 78.95% ±2.26 correct classification rate, 75.00% ±1.34, 76.19%±1.84 sensitivity and 77.78% ±1.14, 82.35% ±1.34 specificity.

Results and Conclusion: The results of the third experiment, with MCI against NC, also showed that the multiclass SVM provided highly accurate classification results. These findings suggest that this approach is efficient and may be a promising strategy for obtaining better AD, MCI and NC classification performance. To read out more, please visit: http://www.eurekaselect.com/166178/article

Become a Reviewer | Current Alzheimer Research

 

Current Alzheimer Research publishes peer-reviewed frontier review, research, drug clinical trial studies and letter articles on all areas of Alzheimer’s disease. This multidisciplinary journal will help in understanding the neurobiology, genetics, pathogenesis, and treatment strategies of Alzheimer’s disease. The journal publishes objective reviews written by experts and leaders actively engaged in research using cellular, molecular, and animal models. The journal also covers original articles on recent research in fast emerging areas of molecular diagnostics, brain imaging, drug development and discovery, and clinical aspects of Alzheimer’s disease. Manuscripts are encouraged that relate to the synergistic mechanism of Alzheimer’s disease with other dementia and neurodegenerative disorders. Book reviews, meeting reports and letters-to-the-editor are also published. The journal is essential reading for researchers, educators and physicians with interest in age-related dementia and Alzheimer’s disease. Current Alzheimer Research provides a comprehensive ‘bird’s-eye view’ of the current state of Alzheimer’s research for neuroscientists, clinicians, health science planners, granting, caregivers and families of this devastating disease.

The Journal Current Alzheimer Research is interested in appointing active Reviewer  on the Journal’s Board. If you are working in the related field as of the journal and are interested in becoming an Reviewer, please send us your CV and a list of publications. If, however, the scope of the journal is not directly related to your field, you can recommend suitable colleagues for the same, and, if possible, send their CV along with their list of publications. Mention in the subject line, the field of interest and send your CV at:

• hermain@benthamscience.net and;
• CC faizan@benthamscience.net

 

Become an Editorial Board Member (EBM) | Current Alzheimer Research

 

Current Alzheimer Research publishes peer-reviewed frontier review, research, drug clinical trial studies and letter articles on all areas of Alzheimer’s disease. This multidisciplinary journal will help in understanding the neurobiology, genetics, pathogenesis, and treatment strategies of Alzheimer’s disease. The journal publishes objective reviews written by experts and leaders actively engaged in research using cellular, molecular, and animal models. The journal also covers original articles on recent research in fast emerging areas of molecular diagnostics, brain imaging, drug development and discovery, and clinical aspects of Alzheimer’s disease. Manuscripts are encouraged that relate to the synergistic mechanism of Alzheimer’s disease with other dementia and neurodegenerative disorders. Book reviews, meeting reports and letters-to-the-editor are also published. The journal is essential reading for researchers, educators and physicians with interest in age-related dementia and Alzheimer’s disease. Current Alzheimer Research provides a comprehensive ‘bird’s-eye view’ of the current state of Alzheimer’s research for neuroscientists, clinicians, health science planners, granting, caregivers and families of this devastating disease.

The Journal Current Alzheimer Research is interested in appointing active Editorial Board Member  on the Journal’s Board. If you are working in the related field as of the journal and are interested in becoming an Editorial Board Member, please send us your CV and a list of publications. If, however, the scope of the journal is not directly related to your field, you can recommend suitable colleagues for the same, and, if possible, send their CV along with their list of publications. Mention in the subject line, the field of interest and send your CV at:

• hermain@benthamscience.net and;
• CC faizan@benthamscience.net

 

Press Release | Autophagy and Mitochondria: Targets in Neurodegenerative Disorders (image)

 

Autophagy is a cellular degradation process that can cause the death of a cell in certain conditions. Autophagy is necessary to maintain cellular homeostasis by clearing out damaged cellular organelles and proteins through certain pathways. Mitochondria are cell organelles responsible for the constant supply of energy to maintain cellular physiology and energy metabolism.

Ashutosh Kumar et al. at the National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India present a review on autophagy in neuronal cells. The researchers believe that autophagy on the neuronal cells can lead to neurodegenerative diseases and countering the effects of this process through targeted drugs can be beneficial in the fight against such diseases. Neuronal cells are more vulnerable to such bioenergetic depletion as most of their function crucially depends on availability of energy derived mainly from mitochondrial function. Any incidence of mitochondrial dysfunction inevitably results in neurodegeneration. Therefore, mitochondrial autophagy (mitophagy) plays an integral role in the onset of neurodegenerative diseases as the instance and failure of these pathways can have destructive effects on cellular homeostasis.

Previous studies show significant association between neurodegenerative disorders and mitochondrial dysfunction and abnormal mitophagy. Abnormal mitophagy leads to the accumulation of protein aggregates and consequential neurodegeneration. Future treatments for neurodegenerative disorders could involve drugs targeting mitochondria and autophagy-related proteins and enzymes. This review discusses the involvement of mitochondrial and autophagy dysfunction in neurodegenerative disorders specifically focusing on Alzheimer’s, Parkinson’s, and Huntington’s disease. Read full press release to find out more at: https://www.eurekalert.org/pub_releases/2018-12/bsp-aam122618.php

 

 

This article by Dr. Ashutosh Kumar et al. is published in CNS & Neurological Disorders – Drug Targets, Volume 17, Issue 9, 2018. The article is Open Access till 31st January, 2019. To obtain the article, please visit: http://www.eurekaselect.com/164678

Become a Reviewer | Current Alzheimer Research

 

Current Alzheimer Research publishes peer-reviewed frontier review, research, drug clinical trial studies and letter articles on all areas of Alzheimer’s disease. This multidisciplinary journal will help in understanding the neurobiology, genetics, pathogenesis, and treatment strategies of Alzheimer’s disease. The journal publishes objective reviews written by experts and leaders actively engaged in research using cellular, molecular, and animal models. The journal also covers original articles on recent research in fast emerging areas of molecular diagnostics, brain imaging, drug development and discovery, and clinical aspects of Alzheimer’s disease. Manuscripts are encouraged that relate to the synergistic mechanism of Alzheimer’s disease with other dementia and neurodegenerative disorders. Book reviews, meeting reports and letters-to-the-editor are also published. The journal is essential reading for researchers, educators and physicians with interest in age-related dementia and Alzheimer’s disease. Current Alzheimer Research provides a comprehensive ‘bird’s-eye view’ of the current state of Alzheimer’s research for neuroscientists, clinicians, health science planners, granting, caregivers and families of this devastating disease.

The Journal Current Alzheimer Research is interested in appointing active Reviewer  on the Journal’s Board. If you are working in the related field as of the journal and are interested in becoming an Reviewer, please send us your CV and a list of publications. If, however, the scope of the journal is not directly related to your field, you can recommend suitable colleagues for the same, and, if possible, send their CV along with their list of publications. Mention in the subject line, the field of interest and send your CV at:

• hermain@benthamscience.net and;
• CC faizan@benthamscience.net

 

Become an Editorial Board Member (EBM) | Current Alzheimer Research

 

Current Alzheimer Research publishes peer-reviewed frontier review, research, drug clinical trial studies and letter articles on all areas of Alzheimer’s disease. This multidisciplinary journal will help in understanding the neurobiology, genetics, pathogenesis, and treatment strategies of Alzheimer’s disease. The journal publishes objective reviews written by experts and leaders actively engaged in research using cellular, molecular, and animal models. The journal also covers original articles on recent research in fast emerging areas of molecular diagnostics, brain imaging, drug development and discovery, and clinical aspects of Alzheimer’s disease. Manuscripts are encouraged that relate to the synergistic mechanism of Alzheimer’s disease with other dementia and neurodegenerative disorders. Book reviews, meeting reports and letters-to-the-editor are also published. The journal is essential reading for researchers, educators and physicians with interest in age-related dementia and Alzheimer’s disease. Current Alzheimer Research provides a comprehensive ‘bird’s-eye view’ of the current state of Alzheimer’s research for neuroscientists, clinicians, health science planners, granting, caregivers and families of this devastating disease.

The Journal Current Alzheimer Research is interested in appointing active Editorial Board Member  on the Journal’s Board. If you are working in the related field as of the journal and are interested in becoming an Editorial Board Member, please send us your CV and a list of publications. If, however, the scope of the journal is not directly related to your field, you can recommend suitable colleagues for the same, and, if possible, send their CV along with their list of publications. Mention in the subject line, the field of interest and send your CV at:

• hermain@benthamscience.net and;
• CC faizan@benthamscience.net

 

Editors Choice Article | Detecting Non-cognitive Features of Prodromal Neurodegenerative Diseases

 

Journal Name: Current Aging Science

Author(s): Alon Seifan, Christine A. Ganzer*, Krista Ryon, Michael Lin, Rahman Mahmudur, Henriquez Adolfo, Cindy Shih, Alan R. Jacobs, Molly Greenwald, Richard S. Isaacson.

 

Background: Prodromal Neurodegenerative Disease (ND) due to tauopathies such as Alzheimer’s Disease (AD) and Synucleinopathies (SN) such as Parkinson’s Disease (PD) and Dementia with Lewy Bodies (DLB) present subtly. Although ND are considered cognitive disorders, in fact ND present with behavioral and even medical symptomatology years to decades prior to the onset of cognitive changes. Recognizing prodromal ND syndromes is a public health priority because ND is common, disabling and expensive. Diagnosing prodromal ND in real world clinical settings is challenging because ND of the same pathology can present with different symptoms in different people. Individual variability in nature and variability in nurture across the life course influence how ND pathology manifests clinically. The objective of this study was to describe how non-cognitive symptoms from behavioral, medical, neurological and psychiatric domains cluster in prodromal and early stages of ND.

Methods: This was an observational study of patients receiving routine clinical care for memory disorders. All patients receiving a standardized evaluation including complete neurological history and examination and standardized brief neuropsychological testing. A Principal Component Analysis (PCA) considering emotion, motor, sensory and sleep factors was performed on the entire sample of patients in order to identify co-occurring symptom clusters. All patients received a consensus diagnosis adjudicated by at least two dementia experts. Patients were grouped into Cognitively Normal, Detectable Cognitive Impairment, and Mild Cognitive Impairment categories due to AD and/or PD/LBD or NOS pathology. Symptom cluster scores were compared between clinical diagnostic groups. Read out full article at: http://www.eurekaselect.com/169580/article

Breakthrough Findings in Alzheimer’s Research

 

An Interview with Professor D. K. Lahiri

Alzheimer’s disease affects an estimated 5.8 million Americans of all ages, and that number is only slated to rise as statistics indicate that someone develops the disease every 65 seconds. Scientists all over the world are working around the clock to find a sustainable treatment for Alzheimer’s that can reverse the symptoms of the disease and raise the quality of life for its sufferers.

To exchange ideas and information about their research, many scientists contribute to peer-reviewed journals. One of those journals, Current Alzheimer Research, is among the top journals in the field of Alzheimer research and is also one of the flagship journals from Bentham Science Publishers. Current Alzheimer Research has been sharing groundbreaking frontier research, drug clinical trial studies, and letters on all areas of Alzheimer’s disease—and it has earned an impact factor of 3.289. This multidisciplinary journal also helps its readers understand the neurobiology, genetics, pathogenesis, and treatment strategies available for Alzheimer’s disease.

Professor Debomoy Lahiri is a professor of neurobiology at Indiana University and the editor-in-chief of Bentham Science’s Current Alzheimer Research. Professor Lahiri has authored over 300 peer-reviewed articles and has received constant research funding by NIH since 1992. Professor Lahiri was recently interviewed by the press team of Indiana University’s School of Medicine about his team’s research on the role of miRNAs on Alzheimer’s disease.

In his interview, Professor Lahiri described the work he and his team have done at his lab on the role of microRNAs in Alzheimer’s disease. He also went into detail on the functions of microRNAs (miRNAs) and the importance of their findings to the research community involved in developing new strategies to treat the disease.

Typically, miRNAs, which are different than messenger RNA (mRNA), do two things. The first thing they are designed to do is slow down the transcription of specific mRNAs to protein. The second thing they do is target a part of an mRNA called the three prime-untranslated region (UTR). Professor Lahiri and his team are studying unusual species of microRNAs and suggest that these species may be the missing link for Alzheimer’s treatments.

“Alzheimer’s disease occurs when there is a buildup of amyloid-beta peptide in plaque (APP) in the brain,” explained Lahiri. “Why these plaques form remains a mystery, but finding ways to regulate and disrupt these plaques is where our research begins.”

One of the normal functions of APP is removing excess iron from cells, which is believed to limit the formation of plaques. Lahiri’s team discovered activity in miR-346, a unique microRNA molecule which is involved in up-regulating the production and subsequent buildup of APP in conjunction with iron-responsive elements. “These findings suggest that a healthy amount of iron, APP, and RNA complexes (a combination called FeAR) must exist to maintain APP homeostasis, which, in turn, is necessary for keeping the brain healthy,” adds Lahiri.

Lahiri’s team is working hard to understand how all of these mechanisms work together and how to harness them to one day create a universal treatment for patients. The team also hopes to understand how someone’s surrounding environment impacts their risk for Alzheimer’s by learning more about how APP regulations of iron become disrupted in late stages of Alzheimer’s disease. This research could potentially open up opportunities for drug regulation that can target amyloids in Alzheimer’s disease patients.

If Lahiri and his team are successful, a treatment like this for Alzheimer’s would change the lives of millions of people struggling with the disease and the lives of their families, friends, and loved ones.

 

The full interview transcript with Lahiri can be read here:
Part 1 | Part 2

 

For more information about Bentham Science Publishers, please visit our website.

You can also connect with Bentham Science on Facebook, Twitter, and LinkedIn.

Open Access Articles | Alzheimer’s Disease Classification Based on Multi-feature Fusion

Author(s): Nuwan Madusanka, Heung-Kook Choi*, Jae-Hong So, Boo-Kyeong Choi.

Journal Name: Current Medical Imaging

In this study, we investigated the fusion of texture and morphometric features as a possible diagnostic biomarker for Alzheimer’s Disease (AD).

In particular, we classified subjects with Alzheimer’s disease, Mild Cognitive Impairment (MCI) and Normal Control (NC) based on texture and morphometric features. Currently, neuropsychiatric categorization provides the ground truth for AD and MCI diagnosis. This can then be supported by biological data such as the results of imaging studies. Cerebral atrophy has been shown to correlate strongly with cognitive symptoms. Hence, Magnetic Resonance (MR) images of the brain are important resources for AD diagnosis. In the proposed method, we used three different types of features identified from structural MR images: Gabor, hippocampus morphometric, and Two Dimensional (2D) and Three Dimensional (3D) Gray Level Co-occurrence Matrix (GLCM). The experimental results, obtained using a 5-fold cross-validated Support Vector Machine (SVM) with 2DGLCM and 3DGLCM multi-feature fusion approaches, indicate that we achieved 81.05% ±1.34, 86.61% ±1.25 correct classification rate with 95% Confidence Interval (CI) falls between (80.75-81.35) and (86.33-86.89) respectively, 83.33%±2.15, 84.21%±1.42 sensitivity and 80.95%±1.52, 85.00%±1.24 specificity in our classification of AD against NC subjects, thus outperforming recent works found in the literature. For the classification of MCI against AD, the SVM achieved a 76.31% ± 2.18, 78.95% ±2.26 correct classification rate, 75.00% ±1.34, 76.19%±1.84 sensitivity and 77.78% ±1.14, 82.35% ±1.34 specificity. Read out full article here: http://www.eurekaselect.com/166178

 

Podcast | Hypertension, Diabetes and Neurodegenerative Diseases: Is there a Clinical Link through the Ca2+/cAMP Signalling Interaction?

Author(s): Leandro Bueno Bergantin*.

Journal Name: Current Hypertension Reviews

 

 

For article details, please visit: http://www.eurekaselect.com/164730/article

To subscribe our YouTube Channel, please click here: https://bit.ly/1lr0czy